VcMMAE (mc-vc-PAB-MMAE) is adrug-linker conjugate for ADCwith potent antitumor activity by using the anti-mitotic agent, monomethylauristatinE (MMAE, a tubulin inhibitor), linked via the lysosomallycleavabledipeptide, valine-citrulline (vc).

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30⁺cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells^[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells^[2].

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models^[2].

1316.63

Solid

C₆₈H₁₀₅N₁₁O₁₅

646502-53-6

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture and light

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

DMSO : ≥ 54 mg/mL(41.01 mM)

H₂O :< 0.1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

• 1.

  VcMMAE is dissolved in DMSO and then diluted with 0.9% NaCl^[3].